Back to News
Market Impact: 0.35
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
Source: PR Newswire
Healthcare & BiotechCorporate Guidance & Outlook
Akeso announced positive overall-survival results from its randomized, double-blind, multicenter registrational Phase III HARMONi-2 (AK112-303) lung-cancer study at the 2026 World Conference on Lung Cancer. The positive Phase III survival data could support the development and potential commercialization outlook for AK112, although the release excerpt provided no efficacy magnitudes, safety details, or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Intel’s stock crashes, knocking $12B from government’s stake
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Nasdaq futures sink 2.3% as Amazon, Intel and Alphabet send AI jitters through stocks
- Why is iShares Semiconductor ETF plunging today?